Article Text

PDF

Sympathetic ophthalmia risk following vitrectomy: should we counsel patients?
  1. DARA J KILMARTIN,
  2. ANDREW D DICK,
  3. JOHN V FORRESTER
  1. Department of Ophthalmology, University of Aberdeen Medical School, Foresterhill, Aberdeen AB25 2ZD
  1. Dara J Kilmartin opt046{at}abdn.ac.uk

Statistics from Altmetric.com

Retinal surgery is being performed with increasing frequency as the advent of newer microsurgical techniques, perfluorocarbon liquids, and silicone oil tamponade has produced greater anatomical and functional success in preserving vision for both primary and repeat retinal surgery.1 With the ageing of the population, and associated increased incidence of retinal detachment and age related macular degeneration, pars plana vitrectomy, in particular, is being increasingly performed with expanding indications, such as for phakic retinal detachment repair, macular hole, submacular and retinal translocation surgery.1 2Sympathetic ophthalmia is a rare disease, with an incidence of 0.03/100 000,3 causing bilateral severe posterior uveitis following penetrating trauma to one eye. Sympathetic ophthalmia has potentially devastating visual consequences if treatment is delayed or inadequate, and usually chronic immunosuppressive therapy is required in order to preserve good vision.4 Formerly, accidental penetrating eye trauma was the main cause but ocular surgery, particularly retinal surgery, has now become the main risk for sympathetic ophthalmia.3 4

The eye is regarded as an immune privileged site with the presence of blood-tissue barriers at the levels of the retinal vascular endothelium and the retinal pigment epithelium (RPE) and the purported lack of intraocular lymphatic drainage.5 Classically, the development of sympathetic ophthalmia requires scleral perforation, allowing previously sequestered ocular autoantigens to access conjunctival lymphatic drainage.6 Evidence for the precise autoantigen responsible in sympathetic ophthalmia is still inconclusive, as retinal antigens in the region of the rod outer segments, such as retinal S-antigen and interphotoreceptor retinoid binding protein, melanin associated antigens, and antigens derived from the RPE and choroid have all been implicated.7

We compared data from a prospective study of all newly diagnosed sympathetic ophthalmia in the United Kingdom between July 1997 and October 1998 with hospital episode statistics from the Department of Health to ascertain retinal surgical risk factors for sympathetic ophthalmia. With informed patient consent, questionnaire data were obtained from UK-wide surveillance of ophthalmologists through the British Ophthalmological Surveillance Unit of the Royal College of Ophthalmologists. The nature of ocular surgical injury was determined in English patients developing sympathetic ophthalmia in the last 12 months of recruitment where the average response rate was 61%. Finished consultant episodes (a period of patient care for one consultant) were counted for retinal surgical procedures for inpatients in NHS hospitals in England between April 1996 and March 1997 (latest figures available) (Table 1). Of nine sympathetic ophthalmia patients with retinal surgery as their causative ocular injury, seven were English. Of these seven patients, five had pars plana vitrectomy, corresponding to a sympathetic ophthalmia risk of one in 799 vitrectomies. A corresponding sympathetic ophthalmia risk of one in 1357 was determined for external retinal detachment repair, and for either pars plana vitrectomy or external retinal detachment repair, a risk of one in 1152 retinal surgical procedures was calculated.

Table 1

Estimated sympathetic ophthalmia (SO) risk after retinal surgery

Figures for new sympathetic ophthalmia cases are likely to be an underestimate owing to underreporting or errors in diagnosis but there may also be an underestimate of the number of retinal surgical procedures performed. Finished consultant episodes do not represent the number of patients undergoing certain operations, and as a patient may have more than one retinal operation within a year, we are unable to determine from these figures the sympathetic ophthalmia risk after a single or multiple retinal surgical procedures. While the data year for finished consultant episodes began 18 months before new sympathetic ophthalmia case data were collected, recent evidence has shown that the median time interval between initiating trauma and sympathetic ophthalmia onset is 12 months3 and the data years chosen are probably appropriate.

The most interesting finding of this study is that the current sympathetic ophthalmia risk of vitrectomy is nearly twice that of external retinal detachment repair, and is more than twice that of the previously reported 0.06% sympathetic ophthalmia risk after vitrectomy.8 Particularly immunogenic risks of pars plana vitrectomy are likely to be due to increased retinal manipulation and breakdown of the blood-retinal barrier, with release of previously sequestered retinal antigens, and possibly subclinical uveal incarceration at wound sites, a known immunogenic risk.9Antigen presenting cells (APCs) in the form of dendritic cells have been found in the iris, ciliary body, and choroid,10 11and operations which may produce uveal exposure, such as iridenclesis or pars plana vitrectomy with chronic access to uveoretinal antigens and APC stimulation, are implicated in sympathetic ophthalmia. Equally, it is not surprising that ocular surgery which causes significant disruption of uveoretinal tissue, such as neodimium:YAG cyclotherapy and again pars plana vitrectomy, are associated with sympathetic ophthalmia.

The current sympathetic ophthalmia risk of vitrectomy is also more than twice the 0.05% risk of infectious endophthalmitis after vitrectomy.12 As patients are usually counselled about the risk of infection after surgery, and as sympathetic ophthalmia has potentially severe consequences, it may now be appropriate to counsel patients about the risk of sympathetic ophthalmia before performing vitrectomy.

References

View Abstract

Footnotes

  • Funding: The Wellcome Trust, Iris Fund for Prevention of Blindness.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.